


Genetic therapy corrects progressive muscle disorder in mice

April 13 2023, by Brandon Chase



Localization of CIC-1 protein. We used antibodies targeting CLC-1, MyHC 2 A, and MyHC 2B proteins to label TA muscles of LR41;Mbnl1^{-/-} treated with Clcn1 ASO or invert oligo for 16 days and untreated WT controls (N = 4 each group). Representative images of each are shown. Fluorescence intensity is 0–20,000 gray scale units. In the merge images, CIC-1 is colored yellow, MyHC 2 A green, MyHC 2X black (unlabeled), and MyHC 2B red. In the WT images, “+” indicates 2 A fibers and “*” indicates 2X fibers in order to highlight the lower CIC-1 intensity evident at the membrane in 2B fibers vs. 2 A or 2X fibers. Size bars = 50 μ m. Credit: *Nature Communications* (2023). DOI:

10.1038/s41467-023-37619-1

People with myotonic dystrophy experience progressive muscle weakness and repeated episodes of painless muscle stiffness called myotonia.

Investigators at Massachusetts General Hospital (MGH) recently used a targeted drug to restore [muscle strength](#) and correct myotonia in mice with [myotonic dystrophy](#). The research, which is published in *Nature Communications*, could lead to new treatments for affected patients.

Myotonia in myotonic dystrophy is caused by abnormal processing (or splicing) of the transcript created from the gene that codes for the muscle chloride channel Clcn1, a protein that controls the flow of chloride ions into [muscle cells](#).

The abnormal splicing leads to a truncated and poorly functioning Clcn1.

Also, the degree of weakness in patients with myotonic dystrophy is associated with higher amounts of oxidative—rather than glycolytic—muscle fibers. These fibers differ in how they obtain energy for contraction.

To correct the abnormal splicing in mice with myotonic dystrophy, a team led by Thurman Wheeler, MD, a neuromuscular researcher at MGH and an associate professor of Neurology at Harvard Medical School, used a genetic therapy involving small pieces of DNA called antisense oligonucleotides (ASOs).

The ASOs were based on a code that targets the abnormal splicing of

Clcn1, and when injected directly into the animals' muscles, the ASOs corrected the abnormality, boosted the abundance of functional Clcn1, increased the amount of glycolytic [muscle fibers](#), and restored muscle health.

"Our findings show that muscle fiber type transitions in myotonic dystrophy result from myotonia and are reversible," says Wheeler. "Our results also support Clcn1-targeting therapies as a way to increase strength and reduce muscle injury in patients."

Additional co-authors include Ningyan Hu, Eunjoo Kim, and Layal Antoury.

More information: Ningyan Hu et al, Correction of Clcn1 alternative splicing reverses muscle fiber type transition in mice with myotonic dystrophy, *Nature Communications* (2023). [DOI: 10.1038/s41467-023-37619-1](#)

Provided by Massachusetts General Hospital

Citation: Genetic therapy corrects progressive muscle disorder in mice (2023, April 13) retrieved 16 April 2023 from <https://medicalxpress.com/news/2023-04-genetic-therapy-muscle-disorder-mice.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.